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Abstract
Our objective was to analyze the evolution of resistance mutations (RM) and viral tropism of multi-drug-resistant (MDR)
strains detected at primary HIV-1 infection (PHI). MDR HIV strain was defined as the presence of genotypic resistance to at
least 1 antiretroviral of the 3 classes. Tropism determinations (CCR5 or CXCR4) were performed on baseline plasma HIV-RNA
and/or PBMC-HIV-DNA samples, then during follow-up using population-based sequencing of V3 loop and phenotypic
tests. Clonal analysis was performed at baseline for env, RT and protease genes, and for HIV-DNA env gene during follow-up.
Five patients were eligible. At baseline, RT, protease and env clones from HIV-RNA and HIV-DNA were highly homogenous
for each patient; genotypic tropism was R5 in 3 (A,B,C) and X4 in 2 patients (D,E). MDR strains persisted in HIV-DNA
throughout follow-up in all patients. For patient A, tropism remained R5 with concordance between phenotypic and
genotypic tests. Clonal analysis on Month (M) 78 HIV-DNA evidenced exclusively R5 (21/21) variants. In patient B, clonal
analysis at M36 showed exclusively R5 variants (19/19) using both genotypic and phenotypic tests. In patient C, baseline
tropism was R5 by genotypic test and R5/X4 by phenotypic test. An expansion of these X4 clones was evidenced by clonal
analysis on M72 HIV-DNA (12/14 X4 and 2/14 R5 variants). In patient D, baseline tropism was X4 with concordance between
both techniques and HIV-RNA and HIV-DNA remained X4-tropic up to M72, confirmed by the clonal analysis. Patient E
harboured highly homogenous X4-using population at baseline; tropism was unchanged at M1 and M18. In all patients, the
initial MDR population was highly homogenous initially, supporting the early expansion of a monoclonal population and its
long-term persistence. X4-tropic variants present at baseline were still exclusive (patients D and E) or dominant (at least one
time point, patient C) far from PHI.
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Introduction
Sexual transmission of HIV-1 resistant strains has been well
documented [1]. The frequency of strains harbouring resistance to
at least one antiretroviral drug at the time of primary HIV-1
infection (PHI) is stable in Europe over the last decade and reaches
approximately 10–12% [2–5]. Moreover, despite a theoretically
impaired fitness [6], multi-drug resistant (MDR) viral strains can
also be transmitted via the sexual route and establish themselves as
the dominant viral population by massively fuelling the cellular
reservoir [7]. Thus, unlike HIV-1 strains developing resistance
mutations on a failing therapy during chronic disease, resistant
HIV-1 strains identified at the time of PHI persist in plasma over
time in a drug-free environment [7,8]. In addition, transmission of
X4-tropic HIV-1 strains at the time of PHI has also been
documented, and the prevalence of X4 strains at the time of PHI
reaches approximately 15% [9–11]. Long-term evolution of such
X4 strains present at the time of PHI is unknown. The clinical
implicationsareof seriousconcernsincemultidrugresistance aswell
as X4-usage can result in treatment failure and rapid clinical
progression [12–17]. Our objective was to characterize intracellular
HIV-DNA in patients with a MDR HIV-1 strain detected at the
time of PHI and to analyze the viral tropism in such patients. We
analysed the temporal evolution of resistance patterns and viral
tropism in plasma virions and in intracellular HIV-DNA extracted
from peripheral blood mononuclear cells (PBMC). Moreover, to
analyzeextensively the viraltropism, we performed a clonal analysis
at baseline and during the follow-up and we classified the virus as
X4 or R5 using both genotypic and phenotypic methods.
Results
Baseline characteristics of patients
Between 1996 and December 2009, 968 patients were included
in the ANRS PRIMO cohort. Among them, five patients (four
men who have sex with men (MSM), one woman) harbored a
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23301MDR strain and were included. This sub- study is exhaustive as all
the patients infected with a MDR strain and included in the
French PRIMO cohort were analyzed. Median time between
estimated date of infection and enrolment in the cohort was 33
days (range 18–71). Their immuno-virological characteristics and
resistance mutational pattern at baseline are summarised in Table
S1. Resistance mutational pattern was identical between plasma
HIV-RNA and intracellular HIV-DNA in all patients. All five
patients harboured a subtype B strain.
When using the SVMgeno2pheno algorithm or the genotypic
rule for tropism determination, three patients (A, B, C) harboured
a CCR5-using strain and the remaining two (D and E) were
infected with a CXCR4-using virus at the time of PHI. Genotypic
analysis yielded similar tropism results between HIV-RNA and
HIV-DNA at baseline. These results were concordant when
tropism determination was performed using the phenotypic assay
on PBMCs, except for patient B who harboured a R5/X4 strain at
baseline. None of the three patients harbouring an HIV-1 strain
using CXCR4 co-receptor at the time of PHI was homozygous for
deletion Delta32 in CCR5 gene (two patients were wild-type
CCR5 homozygous and one was Delta32 heterozygous).
For all five patients, clonal analysis based on reverse
transcriptase (total 148 clones), protease (total 179 clones) and
envelope (total 218 clones) genes from plasma HIV-RNA and
PBMC-HIV-DNA showed a highly homogenous viral population
(Figures 1A, 1B, 1C). Phylogenetic analysis showed intermingled
sequences obtained from circulating virions and intra-cellular
HIV-DNA. All mutations associated with NRTI and NNRTI
resistance were all linked on the same genome in 144/148 variants
and mutations associated with PI resistance were harboured on the
same genome in four patients, patient E harbouring 10/40 clones
without mutation F53L (Figure 1B).
At baseline, all variants present in plasma and in PBMC used
the same co-receptor for a given patient. Clonal analysis of C2V3
region of env gene showed extremely homogenous viral population
in each patient (A: 18/18 CCR5-using variants in HIV-RNA and
23/23 CCR5-using in HIV-DNA; B: 23/23 CCR5-using variants
in HIV-RNA and 23/23 CCR5-using in HIV-DNA; C: 21/21
CCR5-using variants in HIV-RNA and 23/23 CCR5-using in
HIV-DNA; D: 23/23 CXCR4-using variants in HIV-RNA and
21/21 CXCR4-using in HIV-DNA; E: 20/20 CXCR4-using
variants in HIV-RNA and 23/23 CXCR4-using in HIV-DNA)
(Figure 1C and Table S1).
Based on pairwise evolutionary distances, the intra-individual
variability ranged between 0.00% and 0.47% for reverse
transcriptase sequences, 0.00% and 0.75% for protease sequences
and 0.0031% and 0.94% for envelope sequences.
Longitudinal assessment of genotypic resistance tests in
plasma HIV-RNA and cell-associated HIV-DNA
Median follow-up since enrolment was 78 months (range 18–
96). Results are summarised in Table S1. All resistance mutations
persisted in plasma HIV-RNA in patient A up to Month 36 (M36)
except for mutation K103N and V118I in reverse transcriptase
gene that reverted to wild-type. This patient was successfully
treated with persistence of resistant mutations in PBMC-HIV-
DNA up to the end of follow-up (M78).
Resistance mutational pattern was unchanged in patient B in
plasma HIV-RNA and HIV-DNA up to the end of follow-up
(M36) except for mutation 184V that reverted to wild-type M184
in plasma HIV-RNA sampled at M12; this mutation persisted
however in HIV-DNA throughout the 36-month follow-up.
Reverse transcriptase mutations were unchanged in patient C up
to M24 (except for mutation V118I), genotypic resistance test
could not be performed thereafter. Patient D started HAART
early after PHI, resistance mutational pattern was unchanged
(except for mutation K70R which reverted to wild-type and
mutation T215F which shifted to T215S) in HIV-DNA up to
M72, and amplification of HIV-DNA failed on the last sample
available (M84) probably due to very low HIV-DNA load. Patient
E was rapidly treated for hepatitis C infection with pegylated
interferon a and ribavirine, both HIV-RNA and HIV-DNA fell to
undetectable levels as soon as M18.
Longitudinal assessment of viral tropism of HIV-DNA in
PBMC
Results of tropism determination with SVMgeno2pheno
algorithm, the genotypic rule and the phenotypic assay are
summarised in Table S1. For patient A, harbouring a CCR5 strain
at baseline, viral tropism determined by whole population
sequencing was unchanged in PBMC at M36 and M78. Results
were strictly concordant between genotypic and phenotypic tests at
baseline and M78. Clonal analysis of C2V3 region of env gene
from HIV-DNA extracted from available PBMC samples showed
exclusively homogenous variants, 22/22 CCR5-using variants at
M36 and 21/21 CCR5 at M78 (Figure 2A).
Patient B was infected with a highly homogenous CCR5-using
population. The follow-up of patient B revealed a CCR5 strain
determined by genotypic methods at M12, M24 and M36. Results
were strictly concordant between genotypic and phenotypic tests,
at M36. Clonal analysis revealed 19/19 CCR5-using variants at
M36 on PBMCs (Figure 2B).
Patient C was infected with a highly homogenous CCR5-using
population, determined by genotypic method, at the time of PHI.
Interestingly, the phenotype was R5/X4 at baseline while the
genotype was CCR5 both with the SVMgeno2pheno algorithm
and the genotypic rule. During follow-up, viral tropism deter-
mined by whole population sequencing showed a CCR5 virus at
M6, M24, M60. Clonal analysis of C2V3 region from PBMC-
HIV-DNA showed exclusively CCR5-using variants at M6 (23
clones), M24 (18 clones), M60 (22 clones). We observed a change
in the viral tropism in blood cells at M72 with a CXCR4 virus
determined by both genotypic techniques. At the end of the follow-
up (M96), viral tropism determined by bulk-sequencing was still
CCR5 while it was CXCR4 at M72. This result was confirmed by
the clonal analysis which revealed 12/14 clones CXCR4 and 2/14
clones CCR5 (Figure 2C).
Patient D was infected with a highly homogenous CXCR4-
using population determined by both genotypic and phenotypic
methods. Viral tropism determined by whole population sequenc-
ing was unchanged in PBMC at M48, M72 and M84. Phenotypic
test was unavailable at M84. Clonal analysis showed exclusively
homogenous variants, 23/23 CXCR4-using variants at M72
(Figure 2D).
Patient E was infected with a highly homogenous CXCR4-using
population. Viral tropism was unchanged at M1 in plasma
(determined by both genotypic and phenotypic methods) and at
M18 determined by whole population sequencing on blood cells.
Discussion
This is the first study providing longitudinal data on both
resistance mutational pattern and viral tropism of circulating and
archived viral strains in patients infected with a MDR HIV-1 as
soon as primary HIV infection. This is an exhaustive study as all
the patients infected with a MDR strain and included in the
ANRS PRIMO cohort were analyzed in this sub-study. We
confirm that HIV-1 MDR strains can be transmitted via the sexual
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point after infection and establish themselves as the dominant viral
population [7]. Indeed, these five patients acquired HIV-1
through sexual intercourse and no other risk factor for HIV-1
acquisition was declared. Resistance mutations in reverse tran-
scriptase and in protease genes were evident in both circulating
virions and intra-cellular HIV-DNA after a median of 33 days
after estimated date of infection. Moreover, clonal analysis of the
reverse transcriptase and protease genes from plasma HIV-RNA
and from HIV-DNA showed a highly homogenous viral
population in all 5 patients, with no specific compartmentalization
in the cellular compartment. Resistant strains persisted in plasma
HIV-RNA and in infected blood cells in a drug-free environment,
but they also persisted in the cellular reservoir in patients with
suppressed viral replication on HAART. Despite the usual
dynamic processes affecting the pool of infected cells [18], HIV-
DNA isolated from circulating PBMC far from PHI still exhibited
the same resistance mutational pattern than at the time of PHI,
indicating that resistant viruses entering the cellular reservoir early
in infection had not been replaced. This is supported by the
detection of a highly homogenous and exclusively resistant viral
population in the cellular reservoir at the earliest time-point after
infection, with no wild-type variants to overgrow the resistant and
probably less fit variants [19]. Interestingly, mutation M184V with
deleterious impact on viral fitness [20,21] shifted rapidly to wild-
type amino-acid residue in plasma for patient E in the absence of
drug-selective pressure. Reversion of 184V acquired at the time of
PHI has already been described in plasma HIV-RNA [22,23].
However, even if no longer detectable in plasma, we showed that
this resistance mutation persisted in the cellular reservoir up to
M36, which makes rapid re-emergence possible in plasma if
lamivudine or emtricitabine were to be started. Other mutations
with low impact on replicative capacity shifted also to wild-type
amino-acid residue during follow-up and in the absence of drug-
selective pressure.
HIV-1 binds the CCR5 co-receptor early in the course of HIV
infection, and that X4-using viruses emerge later in the course of
HIV disease [24–26]. Balandya et al recently showed that semen
promotes the preferential transmission of R5 tropic HIV strains
[27]. Here we show that CXCR4-using viruses can be sexually
transmitted. Indeed, monophyletic exclusively CXCR4-using
variants were detected in plasma and archived in PBMC of two
patients (D and E) soon after infection with both genotypic and
phenotypic techniques (SVMgeno2pheno algorithm and genotypic
rule; and phenotypic assay). For patient C, we observed a
discrepancy between the genotypic algorithm/rule which classified
the virus as R5 and the phenotypic assay which identified a X4
virus. Of note, none of these three patients (C, D, E) was
homozygous for deletion Delta32 in CCR5 gene. This discordance
between phenotypic and genotypic methods in patient C could be
explained by a better sensitivity of the phenotypic assay in
detecting minor amounts of CXCR4-using viruses [28]. Moreover
during the follow-up of this patient, the clonal analysis at M72
revealed a mixture of CXCR4-using clones and CCR5-using
clones. One limitation with our cloning method is the fact that any
similar sequences coming from a single PCR reaction tube are
likely to represent PCR resampling. The single genome amplifi-
cation would have offered a more reliable approach, but this
method is sometimes difficult to perform with limited material to
start with. Interestingly, Jordan et al have recently showed that
either method is likely to provide a similar measure of population
diversity, provided that an adequate number of PCR templates is
analyzed [29]. Here we analyzed a high number of PCR templates
at baseline, and we are conscious that our method might not be
representative of all variants during follow-up in treated patients
with low plasma HIV-RNA and low intracellular HIV-DNA.
Recent reports suggest that 6–17% of patients get infected with
an CXCR4-using virus at the time of PHI [9–12,17]. This finding
is clinically relevant since X4-usage as soon as PHI has been
associated with severe and rapid progression of HIV disease
[12,13]. Indeed, CD4 cell count was low in patients D and E as
soon as the diagnosis of PHI. Of note, patients C, D and E who
harboured CXCR4-using variants at the time of PHI were also
infected with a MDR strain. In a previous study included 390
patients at the time of PHI, no association was found between the
presence of resistant virus and HIV tropism [9]. However, a trend
towards lower CD4 cell count was observed in patients infected
with a resistant X4/DM-tropic virus in comparison with patients
infected with a resistant CCR5-tropic strain. Such patients might
be at high risk of rapid disease progression [15] and most
importantly, they have limited therapeutic options as soon as PHI.
Moreover, they might be at high risk of fast decline in CD4 cell
count as it was reported in 78 subjects who completed a 12 month
follow-up without undergoing antiretroviral therapy [11]. Other
studies demonstrated an increased risk of developing a clinical
event among patients infected with X4 tropic viruses compared
with R5 viruses [30]. In the MACS cohort, HIV-1 CXCR4-using
was detected more frequently among men who developed
AIDS#11 years after seroconversion than among those who did
not [31]. In the Swiss HIV Cohort Study, the authors showed that
HIV-1 coreceptor usage and CXCR4-specific viral loads strongly
predicted disease progression during cART, independent of CD4
cell count and total viral load [32]. In our study, one patient (E)
described herein and harbouring an CXCR4-using virus at the
time of PHI was not started on HAART until M18, with no
arguments for rapid disease progression or CD4 decline. The two
other patients (patient C and patient D) harbouring an CXCR4-
using strain at the time of PHI were started on HAART at the
time of PHI until M38 and M30 respectively. After HAART
interruption, the two patients were followed until M96 and M84
without disease progression or CD4 decline. Of note, the presence
of multiple resistance mutations in key genes (reverse transcriptase
and protease) might affect viral replicative capacity, thus rendering
such a viral variant less aggressive even if it uses the CXCR4 co-
receptor. However, Markowitz et al have reported on a patient
infected with a MDR and CXCR4-using strain, who experienced
rapid CD4 decline and progression of HIV-related disease soon
after PHI [15]. Of note, as from M6 after PHI, plasma HIV-RNA
was somehow low in our patients when untreated, suggesting they
might be HIV-controllers. Less than 4% of patients enrolled in the
Figure 1. Phylogenetic analysis, based on the neighbour-joining method, of clones of HIV-1 reverse transcriptase gene sequences
(1A), protease gene sequences (1B) and envelope gene sequences (1C) from patients A–E at baseline, demonstrating highly
homogenous circulating and archived variants in each patient. Clones obtained from plasma HIV-1 RNA are in full squares and clones
obtained from PBMC-HIV-1 DNA are in white circles. Resistance mutational pattern in reverse transcriptase gene and in protease gene is shown for
each patient. Clones not harbouring all resistance mutations are indicated. HIV-1 tropism on Figure 1C is determined by genotypic test. Only
bootstrap values $700 are shown. The reference sequence HXB2 was used as an outgroup. Genetic distance is indicated at the top of the figure, and
represents the number of nucleotide substitutions per site. The numbers between brackets indicate the number of strictly identical sequences that
segregate on the same branch.
doi:10.1371/journal.pone.0023301.g001
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HIV-1 replication [33].
In chronically HIV-1 infected antiretroviral naı ¨ve patients
starting HAART, viral tropism was not modified within one year
after HAART initiation [34]. The temporal evolution of CXCR4-
using viruses acquired at the time of PHI has been poorly
documented. We determined HIV-1 tropism on cell-associated
viruses using HIV-DNA extracted from PBMC on the samples
available during the follow-up. In contrast, most studies have
carried out tropism tests on HIV-RNA extracted from the plasma.
A recent report by Raymond et al described the good agreement
between HIV-1 tropism in PBMC and in plasma at the stage of
PHI [12]. Here, we show that the viral population remained
exclusively R5 (patients A and B) or X4 (patients D and E) far from
PHI, supporting the early expansion of a monoclonal viral
population at the time of primary infection. In contrast, a mixture
of viruses was evident in patient C far from PHI. At baseline, the
original virus remained R5 with the genotypic tools while it was
found X4/R5 with the phenotypic assay. At M72, clonal analysis
evidenced a mixture of R5 and CXCR4-tropic variants. There are
four hypotheses to explain this finding. First, variants identified by
our cloning method might not be representative of all variants
present in the cellular reservoir at the time of PHI; we thus might
have missed some CXCR4-using variants in patient C. Of note,
the sensitivity of the TTT assay for detecting minor amounts of
CXCR4-using viruses was 0.5% [28]. Second, immune pressure
exerted on env gene might have promoted genetic evolution within
the V3 loop. This hypothesis is supported by the fact that, as soon
as PHI, intra-individual variability was highest in env gene than in
reverse transcriptase or protease genes. Third, the evolution of co-
receptor usage in some variants might have been promoted by
down or up regulations of the expression of these co-receptors on
the surface of target cells [35]. The fourth hypothesis would be a
recirculation of CXCR4-using strains archived at PHI in the
cellular reservoir and which persisted far from PHI. Overall, our
data suggest that CXCR4-tropic variants present at the time of
PHI remain exclusive or at least dominant far from PHI, with no
possible use of CCR5-antagonists in these patients even far from
PHI.
Despite the usual dynamic process affecting the pool of infected
cells, MDR and CXCR4-using HIV-strains archived at PHI in the
cellular reservoir persisted far from PHI throughout a median 78-
month follow-up. Overall, these data suggest that determination of
viral tropism at the time of PHI might be useful in order to closely
monitor patients harbouring a CXCR4-using strain. Further
studies are needed to assess whether the evidence of a CXCR4-
using virus during PHI can be used as a diagnostic tool with
clinical relevance rather than a prognostic marker.
Methods
Study population
Our study comprised patients presenting with PHI, enrolled in
the multicentre prospective French ANRS PRIMO Cohort
(ANRS CO6) [36–38]. The ethics committee of Cochin Hospital
approved the study and all patients gave their written informed
consent. This observational cohort does not impose guidelines for
systematic treatment of patients presenting with PHI, the decision
of initiating highly active antiretroviral therapy (HAART) or not
relying on the primary care physician in each clinical setting on
the basis of the French guidelines [39].
Primary HIV-infection was identified as previously described
[40]. Briefly, primary HIV-infection had to be assessed by: (a) a
negative or indeterminate HIV ELISA associated with a positive
antigenemia or plasma HIV RNA (b) a Western blot profile
compatible with ongoing seroconversion (incomplete WB with
absence of antibodies to pol proteins) or (c) an initially negative test
for HIV antibody followed within 6 months by a positive HIV
serology.
For all patients enrolled in the PRIMO Cohort, blood plasma
and PBMC or whole blood were collected at inclusion before any
treatment initiation. Patients enrolled in the present study were
selected if (i) they harboured HIV-1 multi-drug-resistant (MDR)
virus in plasma at inclusion defined as: resistant to at least one
nucleoside analogue reverse transcriptase inhibitor (NRTI) and
one non-nucleoside reverse transcriptase inhibitor (NNRTI) and
one protease inhibitor (PI) at time of PHI, and (ii) who had a
minimum of 18-month-follow-up with available stored blood
plasma and peripheral blood mononuclear cells (PBMC) samples.
Quantification of HIV-RNA in blood plasma
HIV RNA was quantified by using the Cobas taqMan HIV-1
v2.0 assay kit (Roche Diagnostics, Meylan, France) according to
the manufacturer’s instructions.
Quantification of HIV-DNA in peripheral blood
mononuclear cells
PBMC were isolated from fresh whole blood by centrifugation
on a one-layer Ficoll Hypaque gradient. PBMC were washed three
times in RPMI medium, then counted and kept as dry pellets at
280uC. Total DNA was extracted from 200 ml of whole blood or
from PBMC pellet using QIAamp DNA mini kit (Qiagen,
Courtaboeuf, France) and HIV-DNA quantified by real-time
PCR (HIV-DNA Biocentric kit, Bandol, France). The real-time
PCR targets a conserved consensus region in the long terminal
repeat (LTR) region of the HIV-1 major group [41,42]. Results
were expressed as log10 number of HIV-DNA copies per 10
6
PBMC.
Genotypic resistance tests
For all patients enrolled in the PRIMO cohort, genotypic
resistance tests were systematically performed. The HIV-1 reverse
transcriptase (RT) and protease genes were amplified from plasma
HIV-RNA and cell-associated HIV-DNA by a single RT-PCR
followed by nested PCR using published primers [43]. For HIV-
DNA, one microgram of DNA extracted from total PBMC was
amplified by PCR. PCR final products were visualized on gels
then purified using the QIAquick PCR Purification HIV kit
(Qiagen,Courtaboeuf, France.). After purification, PCR products
were sequenced using the fluorescent dideoxy-terminator method
(Big Dye Terminator kit, Applied Biosystem, Perkin Elmer, Foster
City, Calif.) on an ABI 3130 Genetic Analyser sequencer (Applied
Figure 2. Longitudinal phylogenetic analysis, based on the neighbour-joining method, of clones of HIV-1 envelope gene from
patient A (2A), B (2B), C (2C) and E (2D). Clones obtained from plasma HIV-1 RNA are in full squares and clones obtained from PBMC-HIV-1 DNA
are in white circles. The most frequent amino-acid sequence of the V3-loop is indicated for each patient in a square. Amino-acid substitutions within
the V3-loop are underlined and correspondent variants are indicated by an arrow for each patient. Only bootstrap values $700 are shown. The
reference sequence HXB2 was used as an outgroup. Genetic distance is indicated at the top of the figure, and represents the number of nucleotide
substitutions per site. The numbers between brackets indicate the number of strictly identical sequences that segregate on the same branch.
doi:10.1371/journal.pone.0023301.g002
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software. The amino acids at codons associated with resistance to
NRTI, NNRTI and PI were identified according to the 2010
International AIDS Society list (www.iasusa.org). HIV drug
resistance was defined according to the 2010 HIV-1 genotypic
resistance interpretation algorithm of the French National Agency
for Research on AIDS (ANRS) (www.hivfrenchresistance.org). In
this study, genotypic resistance tests were performed on paired
stored samples of plasma and PBMC or whole blood collected at
baseline, at month 6 (M6), M12, M18, M24 and then every twelve
months when available.
Genotypic methods for determining virus tropism
Theenv(340 bp)C2V3 regions wereamplifiedfromplasmaHIV-
RNA and intra-cellular HIV-DNA as described elsewhere [9]. We
determined the HIV-1 co-receptor usage of each sample by two
genotypic methods. One was the SVMgeno2pheno algorithm
(available at: http://coreceptor.bioinf.mpi-sb.mpg.de/cgi-bin/
coreceptor.pl). We chose a false-positive rate of 5% for this test to
obtain a high specificity (95%) for the detection of CXCR4 variants.
The other was a genotypic rule based on amino acid residues at
positions 11 and 25 and the overall net charge of V3 [44–46]. One
of the following criteria was required for predicting X4 co-receptor
usage: (i) R or K at position 11 of V3 and/or K at position 25, (ii) R at
position 25 of V3 and a net charge of $+5, or (iii) a net charge of $+6
[28,47,48]. The V3 net charge was calculated by subtracting the
number of negatively charged amino acids (D and E) from the number
of positively charged ones (K and R). Viruses were classified into two
categories: those with the absence (R5) or presence of X4-tropic viruses
(X4 or X4/DM). As the genotypic tests are unable to predict if the
viruses used only the CXCR4 or both the CCR5 and the CXCR4, we
decided to call them X4 for more clarity of the paper.
HIV-1 co-receptor usage of plasma virions and cell associated
virus was determined at baseline and on HIV-DNA extracted
from PBMC samples available during follow-up.
Phenotypic method for determining virus tropism
Phenotypic characterization of HIV-1 tropism was performed
using the Toulouse Tropism Test (TTT) assay [49]. A region
spanning gp120 and the ectodomain of the gp41 env gene of
plasma HIV-RNA was amplified by reverse transcription PCR.
The phenotype of HIV-1 coreceptor usage was determined using a
recombinant virus entry assay, as previously described [28]. The
sensitivity of the assay for detecting minor amounts of CXCR4-
using viruses was 0.5% [28].
Determination of the Delta32 deletion in CCR5 gene
Determination of the Delta32 deletion in CCR5 gene was
performed in patients harbouring an HIV-1 strain using CXCR4
co-receptor at the time of PHI, as described previously [50].
Clones of HIV-RNA and HIV-DNA of reverse transcriptase,
protease and envelope genes
In order to characterize the variants present in plasma and in the
cellular blood reservoir at baseline, i.e. early after PHI, HIV-DNA
reverse transcriptase,protease and envelopegenes PCR products from plasma
and PBMC samples were cloned into the pGEM-T Easy Vector
System (Promega, Charbonnie `res, France) and transformed into
Escherichia coli JM109 competent cells (Promega) as recommended
by the firm. After overnight incubation at 37uC, insertion was
checked by PCR with inner primers on white colonies. Each PCR
product with the correct molecular weight was purified with the
QIAquick PCR purification kit (Qiagen) and then sequenced as
described above. In addition, clones of envelope gene were performed
on intracellular HIV-DNA extracted from the latest available PBMC
sample collected during follow-up. GenBank accession numbers are
JN181579-JN181727 and JN193569-JN194125.
Phylogenetic analysis
All sequences of HIV-RNA and HIV-DNA reverse transcriptase,
protease and envelope genes were aligned with Clustal X 2.0.11 H
software. Pairwise evolutionary distances were estimated with
DNADist, using Kimura’s two-parameter method, then the phyloge-
netic trees were constructed by a neighbour joining method (neighbour
program implemented in the Phylip package) [51]. The reliability of
each tree topology was estimated from 1000 bootstrap replicates [51].
Supporting Information
Table S1 Immunological,-virological characteristics
and resistance mutation patterns at baseline and during
the follow-up. A: patient A-DSV, B: patient B-ODU, C: patient
C-CXK, D: patient D-MDB, E: patient E-ODM. D: day, M:
month, RT: reverse transcriptase, nd: not done, TTT: Toulouse
Tropism Test. TDF: tenofovir, FTC: emtricitabine, ZDV:
zidovudine, NFV: nelfinavir, EFV: efavirenz, FosAPV: fos-
amprenavir. HIV-DNA: log10 copies/10
6 PB.
(DOC)
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